February 7, 2024
Carbapenem Use Guideline
carbapenem, meropenem, ertapenem
February 7, 2024
carbapenem, meropenem, ertapenem
December 1, 2023
UTI, cystitis, pyelonephritis, urinary tract infection, urinary, asymptomatic bacteriuria, catheter associated urinary tract infection, candida Uti, candiduria
September 1, 2023
vancomycin, gentamicin, line, salvage, CLABSI, hemodialysis line, blood, infection
August 1, 2023
sepsis, bloodstream infection, bacteremia, central line-associated bloodstream infection, CLABSI, vancomycin, antibiotics
July 19, 2023
candida, candidemia, C. glabrata, Bloodstream, antifungal, azole, micafungin
March 23, 2023
The guide serves as an antibiotic selection and dosing reference for clinicians who are providing care to pediatric patients with infectious diseases caused by particular Gram-negative pathogens (e.g., Pseudomonas aeruginosa, AmpC-producing Enterobacterales). These topics were purposefully identified due to the variety of antibiotic dosing recommendations available for pediatric patients; however, depending on the organism or site of infection, specific dosing regimens are required to optimize the pharmacokinetic and pharmacodynamic (PKPD) parameters of the bug-drug-site interaction.
March 1, 2023
prophylaxis, operative, surgical, prophy, SSI
January 12, 2023
January 12, 2023
January 3, 2023
This guidance is for use at UNC Children’s Hospital. Only the conditions specifically addressed are included. This document is intended for patients evaluated in the Emergency Department or Urgent Care and discharge home is planned. For dosing recommendations, we recommend using Lexi-Comp or consulting with Pharmacy or Pediatric Infectious Diseases as necessary.
January 3, 2023
This guidance is intended to be used to assist with empiric antibiotic selection in generally healthy (see below) pediatric patients who are admitted to the hospital and diagnosed with or suspected to have one of the infectious conditions listed in the Tables. This document provides guidance only, and as such this document should not supersede clinical judgment. For example, if a child is known to be recently colonized with MRSA and is being treated for skin and soft-tissue infection, MRSA coverage should be included. Likewise, patients who failed treatment with the recommended (or similar) agent may need alternative therapy. Wherever possible, empiric therapy should be refined based on evolving diagnostic information, microbiologic data, and patient status.
March 30, 2022
Aminoglycoside; Gram-negative; Gram-positive;